AR005535A1 - El uso de anticuerpos anti-cd18 para la manufactura de un medicamento para tratar ataques focales isquemicos, articulo de manufactura y equipo que loscomprenden - Google Patents

El uso de anticuerpos anti-cd18 para la manufactura de un medicamento para tratar ataques focales isquemicos, articulo de manufactura y equipo que loscomprenden

Info

Publication number
AR005535A1
AR005535A1 ARP970100281A ARP970100281A AR005535A1 AR 005535 A1 AR005535 A1 AR 005535A1 AR P970100281 A ARP970100281 A AR P970100281A AR P970100281 A ARP970100281 A AR P970100281A AR 005535 A1 AR005535 A1 AR 005535A1
Authority
AR
Argentina
Prior art keywords
manufacture
article
equipment
antibodies
medicinal product
Prior art date
Application number
ARP970100281A
Other languages
English (en)
Original Assignee
Genentech Inc
Univ Vermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Univ Vermont filed Critical Genentech Inc
Publication of AR005535A1 publication Critical patent/AR005535A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Uso de un anticuerpo anti-CD18 para la manufactura de un medicamento útil para tratar ataques isquémicos focales causados por obstrucción de unaarteria cerebral principal en un mamífero, que comprende administrar una cantidad deanticue rpo anti-CD18 al mamífero que es eficaz para aumentar elflujo de sangre cerebral o para reducir el tamano del infarto, en ausencia de remoción de la obstrucción arterial; artículo de manufactura y equipo que loscomprende.
ARP970100281A 1996-01-23 1997-01-23 El uso de anticuerpos anti-cd18 para la manufactura de un medicamento para tratar ataques focales isquemicos, articulo de manufactura y equipo que loscomprenden AR005535A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58998296A 1996-01-23 1996-01-23

Publications (1)

Publication Number Publication Date
AR005535A1 true AR005535A1 (es) 1999-06-23

Family

ID=24360401

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100281A AR005535A1 (es) 1996-01-23 1997-01-23 El uso de anticuerpos anti-cd18 para la manufactura de un medicamento para tratar ataques focales isquemicos, articulo de manufactura y equipo que loscomprenden

Country Status (13)

Country Link
EP (2) EP1297847A3 (es)
JP (1) JP4864175B2 (es)
AR (1) AR005535A1 (es)
AT (1) ATE222774T1 (es)
AU (1) AU724449B2 (es)
CA (1) CA2242414C (es)
DE (1) DE69714966T2 (es)
DK (1) DK0877626T3 (es)
ES (1) ES2183131T3 (es)
IL (1) IL125255A (es)
PT (1) PT877626E (es)
WO (1) WO1997026912A2 (es)
ZA (1) ZA97257B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
WO2000048681A2 (en) * 1999-02-17 2000-08-24 Genentech, Inc. Co-administration of a thrombolytic and an anti-cd18 antibody
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
WO2001070266A2 (en) 2000-03-17 2001-09-27 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
JP2004507448A (ja) * 2000-03-18 2004-03-11 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド 狭窄症関連疾患を抑制するｃｄ−１８結合抗体
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US6870034B2 (en) 2002-02-05 2005-03-22 Genentech, Inc. Protein purification
JP4319979B2 (ja) 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
AU2004265253B2 (en) 2003-07-28 2011-09-01 Genentech, Inc. Reducing protein A leaching during protein A affinity chromatography
CA2550155C (en) 2003-12-15 2015-03-17 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
JP5902367B2 (ja) * 2004-06-30 2016-04-13 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 抗体
US7501119B2 (en) 2004-06-30 2009-03-10 Mayo Foundation For Medical Education And Research Methods and molecules for modulating an immune response
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
EP2120915B1 (en) 2007-01-22 2011-09-28 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
LT3597659T (lt) 2007-07-09 2023-05-10 Genentech, Inc. Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu
PL2840090T3 (pl) 2007-10-30 2018-07-31 Genentech, Inc. Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
SI2848625T1 (sl) 2008-08-14 2019-11-29 Genentech Inc Postopki za odstranjevanje kontaminanta z uporabo ionskoizmenjevalne membranske kromatografije z izpodrinjenjem nativnega proteina
EP2334323A2 (en) 2008-09-10 2011-06-22 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
CN105037535A (zh) 2008-12-16 2015-11-11 Emd密理博公司 搅拌槽反应器及方法
CA2752884A1 (en) 2009-02-27 2010-09-02 Genentech, Inc. Methods and compositions for protein labelling
PT2464725T (pt) 2009-08-11 2020-05-21 Hoffmann La Roche Produção de proteínas em meios de cultura celular isentos de glutamina
WO2011028753A1 (en) 2009-09-01 2011-03-10 Genentech, Inc. Enhanced protein purification through a modified protein a elution
ES2722201T3 (es) 2010-03-22 2019-08-08 Hoffmann La Roche Composiciones y procedimientos útiles para estabilizar formulaciones que contienen proteínas
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
EP3597671B1 (en) 2010-05-17 2022-09-21 EMD Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
ES2599412T3 (es) 2010-05-28 2017-02-01 F. Hoffmann-La Roche Ag Disminución del nivel de lactato y aumento de la producción de polipéptidos regulando por disminución la expresión de la lactato deshidrogenasa y de la piruvato deshidrogenasa quinasa
MY184736A (en) 2010-06-24 2021-04-20 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
EP2603525A1 (en) 2010-08-13 2013-06-19 F.Hoffmann-La Roche Ag Antibodies to il-1beta and il-18, for treatment of disease
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
EP2732021B1 (en) 2011-07-08 2020-05-27 EMD Millipore Corporation Improved depth filters for disposable biotechnological processes
BR112014015101A8 (pt) 2011-12-22 2021-06-08 Genentech Inc métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos
MX365947B (es) 2012-03-27 2019-06-19 Genentech Inc Operaciones de cosecha mejoradas para proteinas recombinadas.
CA2873646C (en) 2012-05-18 2022-04-26 Genentech, Inc. High-concentration monoclonal antibody formulations
CN104994885B (zh) 2012-12-19 2017-09-29 基因泰克公司 用于放射性卤素蛋白质标记的方法和组合物
KR102355306B1 (ko) 2014-07-09 2022-01-24 제넨테크, 인크. 세포 은행의 해동 회수를 개선하는 ph 조정
AU2017242031B2 (en) 2016-03-29 2023-07-27 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
AU2017382281A1 (en) 2016-12-22 2019-06-13 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
BR112020025623A2 (pt) 2018-07-03 2021-03-23 Bristol-Myers Squibb Company métodos de produção de proteínas recombinantes
EP3864127A1 (en) 2018-10-10 2021-08-18 Boehringer Ingelheim International GmbH Method for membrane gas transfer in high density bioreactor culture
MX2021012032A (es) 2019-04-01 2021-11-03 Genentech Inc Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
WO2020210440A1 (en) 2019-04-12 2020-10-15 Geltor, Inc. Recombinant elastin and production thereof
US20220315887A1 (en) 2019-08-01 2022-10-06 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
WO2022066595A1 (en) 2020-09-22 2022-03-31 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2119128C (en) * 1992-07-16 2000-05-30 Lynn M. Rose Alleviation of symptoms associated with inflammatory disease states
AU5732694A (en) * 1992-12-01 1994-06-22 Protein Design Labs, Inc. Humanized antibodies reactive with cd18

Also Published As

Publication number Publication date
DE69714966D1 (de) 2002-10-02
DE69714966T2 (de) 2003-04-24
WO1997026912A3 (en) 1997-10-09
AU1827397A (en) 1997-08-20
ATE222774T1 (de) 2002-09-15
DK0877626T3 (da) 2002-12-30
WO1997026912A2 (en) 1997-07-31
IL125255A (en) 2002-02-10
PT877626E (pt) 2003-01-31
JP2000517289A (ja) 2000-12-26
AU724449B2 (en) 2000-09-21
CA2242414A1 (en) 1997-07-31
EP1297847A2 (en) 2003-04-02
CA2242414C (en) 2012-01-03
EP0877626B1 (en) 2002-08-28
JP4864175B2 (ja) 2012-02-01
EP1297847A3 (en) 2003-05-07
ZA97257B (en) 1998-07-14
ES2183131T3 (es) 2003-03-16
EP0877626A2 (en) 1998-11-18
IL125255A0 (en) 1999-03-12

Similar Documents

Publication Publication Date Title
AR005535A1 (es) El uso de anticuerpos anti-cd18 para la manufactura de un medicamento para tratar ataques focales isquemicos, articulo de manufactura y equipo que loscomprenden
NO304346B1 (no) Absorberende artikler innbefattende superabsorbensmateriale som har forsinket aktiveringstid
SE8602943L (sv) For engangsanvendning avsedd vetskeabsorberande artikel
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
DK1014996T3 (da) Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
BR9913157A (pt) Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto
DK0751781T3 (da) Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
CO5070671A1 (es) Un articulo absorbente que tiene un laminado de material que comprende una lamina superior permeable a los liquidos y una lamina de transferencia de liquido permeable a los liquidos
FI922870A (fi) Absorberande engaongsprodukt, som aer indelad i delar i dess laengdriktning.
ES2115618T3 (es) Uso de anticuerpos anti-icam en la preparacion de un medicamento para el tratamiento del choque por endotoxinas.
RU93004982A (ru) Способ лечения эндотоксинового шока с применением антиадгезивных антител
KR950701820A (ko) 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
DE68921150D1 (de) Wirkung von hormonen.
DE69125855D1 (de) Therapeutisch wirksame, örtliche anwendung von st1435
ES2055314T3 (es) Tratamiento de disfuncion leucocitaria con gm-csf.
DE69909747D1 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
ES2117046T3 (es) Anticuerpo anti-factor de crecimiento en el tratamiento de estenosis vascular.
BR9916043A (pt) Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes
ES2151922T3 (es) Uso de aspirina para la fabricacion de un medicamento para mejorar la perfusion sanguinea en el utero.
AR012638A1 (es) Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional
AR010344A1 (es) Uso de equilenina o una sal farmaceuticamente aceptable del ester de equilenina-3-sulfato para la manufactura de un medicamento util para inhibir otratar patologias inducidas por los radicales libres y composiciones farmaceuticas
CO5011042A1 (es) Uso de una oxazolidinona para la fabricacion de un medicamento para administracion topica
AR010336A1 (es) Uso de 17 alfa-dihidroequilenina o una sal farmaceuticamente aceptable del ester 17 alfa-dihidroequilenina-3-sulfato para la manufactura de un medicamentoutil para inhibir o tratar patologias inducidas por los radicales libres y una composicion farmaceutica.
BR9609868A (pt) Conjugado sintético de uma proteína e uma pluralidade de epítopos para uso em medicina processos para evitar a rejeição de um xenoenxerto ou pelo menos reduzir a extensão ou taxa de rejeição para tratar uma doença e sangue removido de um doador de sangue aparelho sangue composição farmaceuticamente aceitável e uso de um conjugado